Risk stratification has gained an increasing role in predicting outcomes and guiding the
treatment of patients with pulmonary arterial hypertension (PAH). The most predictive …

Background In pulmonary arterial hypertension, it is recommended to base therapeutic
decisions on risk stratification. This systematic review aims to report the prognostic value of …

Background Multiparametric risk assessment tools determine mortality risk in patients with
pulmonary arterial hypertension (PAH) by combining invasive and noninvasive variables so …

Risk stratification in pulmonary arterial hypertension (PAH) is crucial in assessing patient
prognosis. It serves a prominent role in everyday patient care and can be determined using …

Right heart (RH) structure and function are major determinants of symptoms and prognosis
in pulmonary arterial hypertension (PAH). RH imaging provides detailed information, but …

Treprostinil is a prostacyclin analogue that targets multiple cellular receptors to treat
pulmonary arterial hypertension (PAH). In certain scenarios, patients may require …

SSc-associated myocardial disease remains challenging to predict, yet novel imaging
modalities and biomarker-guided strategies offer a promising pathway for early diagnosis …

Pulmonary arterial hypertension (PAH) is a chronic and progressive disease that eventually
leads to heart failure (HF) and subsequent fatality if left untreated. Right ventricular (RV) …

Introduction Elderly patients in immunosuppressive status may have an increased
occurrence of illness and risk of poor prognosis. It is a generally overlooked population that …

Rationale Oral treprostinil slows disease progression and improves exercise capacity in
pulmonary arterial hypertension; however, titration can be prolonged. Published data …